Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

InVivo Therapeutics

Request full access

InVivo Therapeutics (NASDAQ:NVIV) is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

Cambridge, United StatesFounded 2005Biotech & Life Sciences

About InVivo Therapeutics

InVivo Therapeutics is a pioneering company focused on developing innovative treatments for spinal cord injuries (SCI). Operating in the biotechnology sector, InVivo targets a critical unmet medical need by advancing clinical research and development to improve the lives of SCI patients. The company primarily serves patients with acute spinal cord injuries, collaborating with healthcare providers and research institutions to bring cutting-edge therapies to market. InVivo's business model revolves around the development and commercialization of its proprietary technologies, including the Neuro-Spinal Scaffold, which is designed to promote structural support and healing in the spinal cord. Revenue is generated through a combination of product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies. The company is committed to rigorous clinical trials to validate the efficacy and safety of its treatments, ensuring regulatory compliance and striving for market approval. InVivo's market is global, with a focus on regions with high incidences of spinal cord injuries and robust healthcare infrastructures. Key stakeholders include patients, healthcare providers, research institutions, and investors who are aligned with the company's mission to redefine the life of spinal cord injury patients.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2010

InVivo Therapeutics in the Cambridge ecosystem

Live from Dealroom

The InVivo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • Spencer trask & co
  • Lincoln Park Capital Fund
  • SternAegis Ventures
Team profiled 21 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about InVivo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See InVivo Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.